Address: Dandyvej 19, DK-7100 Vejle, Denmark
Tel: +45 7215 1300
Web: fertin.com
Fertin Pharma aims to be one of the leading suppliers of selected medical dispensation forms within relevant therapeutic areas.Fertin Pharma is a world leader in the development and manufacture of medical chewing gum. Our largest product category is smoking cessation chewing gum.
Our largest product category is smoking cessation chewing gum.
Bavarian Nordic’s 2012 financial results were very positive, with annual revenues doubling. How satisfied were you with this performance, and which factors drove this growth? We were extremely satisfied with…
Beginning his career in Bayer Pharma Mr. Drøidal soon found his calling in management, working his way up the ranks of management in Pfizer reaching the position of Head of…
Could you outline the significance of Denmark to IBM’s global operations? Industry in Denmark works with government on a basis of trust rather than mistrust. That means that we have…
As Novo Nordisk is celebrating its 90 year anniversary this year, may you please begin this interview by discussing how the company, since its beginning, has changed the face of…
Novo Nordisk CEO Lars Rebien Sørensen discusses the company’s commitment to curing diabetes, his own history with the organisation, and the values that have served Novo Nordisk so well in their…
What is Pfizer’s current position in the Danish market? We are first or second in the market, depending on how you count. There are two unique factors about the Danish…
Can you please tell our readers, what were some of ALK’s highlights in 2012? We had several important milestones in 2012. We advanced our research and development pipeline and made…
Why did MSD decide to have Denmark as the headquarters for the Mid Europe 2 region? This Mid Europe 2 region consists of 10 countries, most of them clustered around the…
After establishing the operations of ChemPartner in 2009, can you tell our readers why Denmark? ChemPartner is a leading contract research laboratory within drug discovery. When ChemPartner was openly reviewing…
The last years have been challenging Sanofi since many of your historic blockbuster drugs that have driven the growth of Sanofi in the past, have faced patent expiration and loss…
After working for 18 years in Nycomed in very stable corporate positions, what drove you to invest everything that you had in this company? Where did you see the potential…
Usually the main issue when it comes to rare diseases is identifying patients. In Denmark we hear that because of the country’s efficient social security system everyone is fairly well…
See our Cookie Privacy Policy Here
